U.S. Markets open in 6 hrs 56 mins

Elite Pharmaceuticals, Inc. (ELTP)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.193-0.01 (-3.17%)
At close: 3:58PM EDT
People also watch
AMBSONCSIGXTRNNMSTX
Full screen
Previous Close0.199
Open0.000
Bid0.000 x
Ask0.000 x
Day's Range0.000 - 0.000
52 Week Range
Volume0
Avg. Volume1,021,792
Market Cap149.68M
Beta0.34
PE Ratio (TTM)-27.57
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q4, 2017 By the Numbers : June 16, 2017
    Capital Cube10 days ago

    Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q4, 2017 By the Numbers : June 16, 2017

    Categories: Yahoo FinanceGet free summary analysis Elite Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Elite Pharmaceuticals, Inc. – Mylan N.V., Acura Pharmaceuticals, Inc., Cambrex Corporation, Aceto Corporation, Nektar Therapeutics, Pfizer Inc. and Albany Molecular Research, Inc. (MYL-US, ACUR-US, CBM-US, ACET-US, NKTR-US, PFE-US ... Read more (Read more...)

  • Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q3, 2017 By the Numbers : March 15, 2017
    Capital Cube3 months ago

    Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q3, 2017 By the Numbers : March 15, 2017

    Categories: Yahoo Finance Get free summary analysis Elite Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Elite Pharmaceuticals, Inc. – Mylan N.V., Cambrex Corporation, Aceto Corporation, Nektar Therapeutics, Pfizer Inc., Albany Molecular Research, Inc. and Akorn, Inc. (MYL-US, CBM-US, ACET-US, NKTR-US, PFE-US, AMRI-US and ... Read more (Read more...)

  • TheStreet.com10 months ago

    Trending Tickers: CZR, APO, MCUR, KS, ELTP

    Caesars shares sink after a judge ruled that it would not be shielded from $11 billion in bondholder lawsuits.